Sign inCreate account

Report workspace

Add to folder
NCT06980259RECRUITINGanonymous

Spatially Fractionated Radiotherapy Versus Conventional Radiotherapy in the Treatment of Soft Tissue Sarcoma:A Multicenter，Prospective, Phase II, Randomized Controlled Trial

Sponsor

Source record

Shandong Cancer Hospital and Institute

Phase

Source record

Phase 2

Modality

AI-normalized

RNA therapy

Target

AI-normalized

Spatially Fractionated Radiation Therapy (SFRT) aims to enhance tumor control in soft tissue sarcoma (STS) through a combination of conventional radiation therapy (CRT) and high-dose radiation vertices, potentially stimulating immune responses.

Indication / condition

AI-normalized

Soft Tissue Sarcoma (STS)

Intervention

Source record

Spatially Fractionated Radiotherapy, Conventional Radiotherapy

Source & freshness

Source record

NCT ID

NCT06980259

Original source

ClinicalTrials.gov

Source last updated

Apr 28, 2026

Ingested at

Jun 17, 2026

Internal sync

Jun 17, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT06980259

Title

Spatially Fractionated Radiotherapy Versus Conventional Radiotherapy in the Treatment of Soft Tissue Sarcoma:A Multicenter，Prospective, Phase II, Randomized Controlled Trial

Sponsor

Shandong Cancer Hospital and Institute

Status

RECRUITING

Phase

Phase 2

Condition raw

Soft Tissue Sarcoma (STS)

Condition normalized

Soft Tissue Sarcoma (STS)

Modality raw

RNA therapy

Modality normalized

RNA therapy

Target raw

Spatially Fractionated Radiation Therapy (SFRT) aims to enhance tumor control in soft tissue sarcoma (STS) through a combination of conventional radiation therapy (CRT) and high-dose radiation vertices, potentially stimulating immune responses.

Target normalized

Spatially Fractionated Radiation Therapy (SFRT) aims to enhance tumor control in soft tissue sarcoma (STS) through a combination of conventional radiation therapy (CRT) and high-dose radiation vertices, potentially stimulating immune responses.

Interventions

Spatially Fractionated Radiotherapy, Conventional Radiotherapy

Public preview

Source record

This multicenter, randomized controlled trial is pivotal in evaluating the efficacy and safety of SFRT compared to CRT in treating STS, a malignancy with historically low radiosensitivity. If successful, SFRT could represent a significant advancement in radiotherapy for STS, potentially capturing a share of the oncology market focused on innovative treatment modalities. The trial's outcomes may influence treatment guidelines and establish a competitive edge for the sponsoring institution, Shandong Cancer Hospital and Institute, in the field of radiation oncology. The results could also attract interest from pharmaceutical companies looking to partner on further development or commercialization.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Spatially Fractionated Radiotherapy Versus Conventional Radiotherapy in the Treatment of Soft Tissue Sarcoma:A Multicenter，Prospective, Phase II, Randomized Controlled Trial

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 17, 2026

NCT ID

NCT06980259

Status

RECRUITING

Phase

Phase 2

Sponsor

Shandong Cancer Hospital and Institute

Executive brief

Investment-Ready Snapshot

This multicenter, randomized controlled trial is pivotal in evaluating the efficacy and safety of SFRT compared to CRT in treating STS, a malignancy with historically low radiosensitivity. If successful, SFRT could represent a significant advancement in radiotherapy for STS, potentially capturing a share of the oncology market focused on innovative treatment modalities. The trial's outcomes may influence treatment guidelines and establish a competitive edge for the sponsoring institution, Shandong Cancer Hospital and Institute, in the field of radiation oncology. The results could also attract interest from pharmaceutical companies looking to partner on further development or commercialization.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedApr 28, 2026
Internal syncJun 17, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT06980259

Indication

Soft Tissue Sarcoma (STS)

Modality

RNA therapy

Target

Spatially Fractionated Radiation Therapy (SFRT) aims to enhance tumor control in soft tissue sarcoma (STS) through a combination of conventional radiation therapy (CRT) and high-dose radiation vertices, potentially stimulating immune responses.

Intervention

Spatially Fractionated Radiotherapy, Conventional Radiotherapy

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.